title: Drug-Induced Subacute Cutaneous Lupus Erythematosus in a Patient Receiving Therapy for Chronic Hepatitis C.
abstract: Hepatitis C infection and its treatment have been associated with extrahepatic manifestations, including different skin conditions. Over the past decades, a greater number of drugs have been implicated as triggers for drug-induced subacute cutaneous lupus erythematosus. We report a case of a 42-year-old Hispanic man who developed a forehead violaceous rash during treatment with pegylated interferon alpha-2a as part of his therapy against hepatitis C infection that subsequently resulted to be subacute cutaneous lupus erythematosus. The skin lesion improved with discontinuation of medication and some topic therapy.
authors.affiliation: Department of Medicine, New York Medical College, Metropolitan Hospital Center, New York, NY.
authors.forename: Hans A
authors.initials: HA
authors.lastname: Reyes
authors.forename: Eder H
authors.initials: EH
authors.lastname: Cativo
authors.forename: Alexander M
authors.initials: AM
authors.lastname: Sy
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D009842:Oligopeptides / Q000009:adverse effects*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000009:adverse effects; D012254:Ribavirin / Q000009:adverse effects*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C100416:peginterferon alfa-2a